Change search
ReferencesLink to record
Permanent link

Direct link
Fatty acid synthase is a metabolic oncogene targetable in malignant peripheral nerve sheath tumors
Umeå University, Faculty of Medicine, Department of Radiation Sciences, Oncology.
Show others and affiliations
2015 (English)In: Neuro-Oncology, ISSN 1522-8517, E-ISSN 1523-5866, Vol. 17, no 12, 1599-1608 p.Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Malignant peripheral nerve sheath tumors (MPNSTs) are soft tissue sarcomas with minimal therapeutic opportunities. We observed that lipid droplets (LDs) accumulate in human MPNST cell lines and in primary human tumor samples. The goal of this study was to investigate the relevance of lipid metabolism to MPNST survival and as a possible therapeutic target.

METHODS: Based on preliminary findings that MPNSTs accumulate LDs, we hypothesized that a deregulated lipid metabolism supports MPNST cell survival/proliferation rate. To test this, we examined respiration, role of fatty acid oxidation (FAO), and the enzyme fatty acid synthase involved in de novo fatty acid synthesis in MPNSTs using both genetic and pharmacological tools.

RESULTS: We demonstrate that LDs accumulate in MPNST cell lines, primary human and mouse MPNST tumors, and neural crest cells. LDs from MPNST cells disappear on lipid deprivation, indicating that LDs can be oxidized as a source of energy. Inhibition of FAO decreased oxygen consumption and reduced MPNST survival, indicating that MPNST cells likely metabolize LDs through active FAO. FAO inhibition reduced oxygen consumption and survival even in the absence of exogenous lipids, indicating that lipids synthesized de novo can also be oxidized. Consequently, inhibition of de novo fatty acid synthesis, which is overexpressed in human MPNST cell lines, effectively reduced MPNST survival and delayed induction of tumor growth in vivo.

CONCLUSION: Our results show that MPNSTs depend on lipid metabolic pathways and suggest that disrupting lipid metabolism could be a potential new strategy for the development of MPNST therapeutics.

Place, publisher, year, edition, pages
2015. Vol. 17, no 12, 1599-1608 p.
Keyword [en]
Animals, Antineoplastic Agents/*therapeutic use, Cell Death, Cell Line, Tumor, *Drug Screening Assays, Antitumor, Humans, Immunosuppressive Agents/therapeutic use, Mice, Mice, Nude, Nerve Sheath Neoplasms/*drug therapy/metabolism, Protein Kinases/*metabolism, Quinazolines/pharmacology, Ribosomal Protein S6 Kinases, 70-kDa/metabolism, Signal Transduction, Sirolimus/*analogs & derivatives/therapeutic use, TOR Serine-Threonine Kinases, Up-Regulation
National Category
Cell Biology
URN: urn:nbn:se:umu:diva-106956DOI: 10.1093/neuonc/nov076ISI: 000368452700008PubMedID: 26116612OAI: diva2:845810
Available from: 2015-08-13 Created: 2015-08-13 Last updated: 2016-02-24Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Johansson, Gunnar
By organisation
In the same journal
Cell Biology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 22 hits
ReferencesLink to record
Permanent link

Direct link